Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.

Andréo U, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M, Marcellin P, Budkowska A.

Cell Microbiol. 2007 Oct;9(10):2445-56. Epub 2007 May 21.

PMID:
17517063
2.

Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Dreux M, Dao Thi VL, Fresquet J, Guérin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B.

PLoS Pathog. 2009 Feb;5(2):e1000310. doi: 10.1371/journal.ppat.1000310. Epub 2009 Feb 20.

4.

Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.

Maillard P, Walic M, Meuleman P, Roohvand F, Huby T, Le Goff W, Leroux-Roels G, Pécheur EI, Budkowska A.

PLoS One. 2011;6(10):e26637. doi: 10.1371/journal.pone.0026637. Epub 2011 Oct 21.

5.

Lipoprotein lipase-mediated uptake of lipoprotein in human fibroblasts: evidence for an LDL receptor-independent internalization pathway.

Fernández-Borja M, Bellido D, Vilella E, Olivecrona G, Vilaró S.

J Lipid Res. 1996 Mar;37(3):464-81.

6.

Hepatitis C virus cell entry: role of lipoproteins and cellular receptors.

Burlone ME, Budkowska A.

J Gen Virol. 2009 May;90(Pt 5):1055-70. doi: 10.1099/vir.0.008300-0. Epub 2009 Mar 4. Review.

PMID:
19264629
7.

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL.

J Biol Chem. 2003 Oct 24;278(43):41624-30. Epub 2003 Aug 11.

8.

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL.

J Biol Chem. 2006 Jul 7;281(27):18285-95. Epub 2006 May 4.

9.

The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins.

Maillard P, Huby T, Andréo U, Moreau M, Chapman J, Budkowska A.

FASEB J. 2006 Apr;20(6):735-7. Epub 2006 Feb 13.

PMID:
16476701
10.

Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins.

Shimizu Y, Hishiki T, Sugiyama K, Ogawa K, Funami K, Kato A, Ohsaki Y, Fujimoto T, Takaku H, Shimotohno K.

Virology. 2010 Nov 10;407(1):152-9. doi: 10.1016/j.virol.2010.08.011. Epub 2010 Sep 6.

11.

Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo.

Heeren J, Niemeier A, Merkel M, Beisiegel U.

J Mol Med (Berl). 2002 Sep;80(9):576-84. Epub 2002 Jun 18.

PMID:
12226739
13.
14.

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry.

Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoeur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L.

BMC Microbiol. 2009 May 28;9:111. doi: 10.1186/1471-2180-9-111.

15.

Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.

Sun HY, Lin CC, Lee JC, Wang SW, Cheng PN, Wu IC, Chang TT, Lai MD, Shieh DB, Young KC.

Gut. 2013 Aug;62(8):1193-203. doi: 10.1136/gutjnl-2011-301798. Epub 2012 Jun 11.

PMID:
22689516
16.

High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.

Voisset C, Op de Beeck A, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J.

J Gen Virol. 2006 Sep;87(Pt 9):2577-81.

PMID:
16894196
17.

Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway.

Fuki IV, Blanchard N, Jin W, Marchadier DH, Millar JS, Glick JM, Rader DJ.

J Biol Chem. 2003 Sep 5;278(36):34331-8. Epub 2003 Jun 16.

18.

Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E.

Lefèvre M, Felmlee DJ, Parnot M, Baumert TF, Schuster C.

PLoS One. 2014 Apr 21;9(4):e95550. doi: 10.1371/journal.pone.0095550. eCollection 2014.

19.
20.

The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.

Perrault M, Pécheur EI.

Biochem J. 2009 Oct 12;423(3):303-14. doi: 10.1042/BJ20091000. Review.

PMID:
19807698

Supplemental Content

Support Center